Psilocybin-Assisted Therapy (PAT)

Psilocybin-assisted therapy is an emerging treatment currently being studied in clinical trials around the world. Psilocybin is a naturally occurring compound found in certain species of mushrooms. When administered in controlled therapeutic settings, psilocybin may help individuals access emotional insights and shift patterns of rigid thinking.

Research suggests that psilocybin may support meaningful psychological change when combined with psychotherapy.

What is Psilocybin-Assisted Therapy?

Psilocybin-assisted therapy combines structured psychotherapy with the administration of psilocybin in a controlled clinical setting.

Psilocybin affects serotonin receptors in the brain, particularly the 5-HT2A receptor, which plays an important role in mood, perception, and emotional processing.

Brain imaging studies show that psilocybin may temporarily reduce activity in the default mode network, a brain system linked to rumination and repetitive negative thinking.

This temporary shift may allow individuals to process difficult emotions or memories from a new perspective.

Conditions Being Studied

Researchers are currently studying psilocybin therapy for several conditions, including:

• Major depressive disorder
• Treatment-resistant depression
• Alcohol use disorder
• Smoking cessation
• End-of-life anxiety in patients with serious illness
• Obsessive compulsive disorder

Many of these studies have shown significant symptom improvement in participants.

Current Research Findings

Early clinical trials have reported encouraging results.

Research suggests:

• Around 60 to 70 percent of patients with treatment-resistant depression show meaningful improvement after psilocybin therapy.
• In some studies, symptom improvements lasted three to six months or longer.
• Research on alcohol use disorder and smoking cessation has shown reductions in substance use following treatment.

Because many of these studies involve relatively small groups, larger clinical trials are currently underway.

Legal Status

Psilocybin is currently classified as a Schedule I substance under U.S. federal law, meaning it is not yet approved for medical use.

However, clinical trials are advancing quickly.

The FDA granted Breakthrough Therapy designation to psilocybin therapy for depression, which helps accelerate the research and review process.

Many experts believe psilocybin-assisted therapy may receive FDA approval for depression around 2026, pending results from ongoing Phase 3 trials.

Some states and cities have also begun exploring limited policy changes regarding psilocybin research and decriminalization.

The Future of Psilocybin Therapy

Researchers are continuing to study how psilocybin therapy may help individuals with difficult-to-treat mental health conditions.

Areas of ongoing research include:

• Long-term effects of psilocybin therapy
• Best therapeutic frameworks for treatment
• Integration therapy and psychological support
• Safety screening and patient selection

If approved by the FDA, psilocybin-assisted therapy may become an important option for individuals who have not responded to traditional treatments.

What is My Rule As a Therapist

My role as your therapist is to create a space where you feel safe, supported, and respected throughout the process. I focus on preparation and integration around sublingual ketamine supported psychotherapy, helping you stay grounded, make sense of your experiences, and turn insight into real change in your daily life.

I do not prescribe medication or provide medical supervision, and I work closely within my scope as a therapist while collaborating with your licensed medical provider. My intention is to walk alongside you with curiosity, compassion, and clear boundaries, so you feel guided, not pushed, and always connected to your own pace and inner wisdom.